Cargando…

Rotigotine Effects on Early Morning Motor Function and Sleep in Parkinson's Disease: A Double-Blind, Randomized, pLacebo-Controlled Study (RECOVER)

In a multinational, double-blind, placebo-controlled trial (NCT00474058), 287 subjects with Parkinson's disease (PD) and unsatisfactory early-morning motor symptom control were randomized 2:1 to receive rotigotine (2–16 mg/24 hr [n = 190]) or placebo (n = 97). Treatment was titrated to optimal...

Descripción completa

Detalles Bibliográficos
Autores principales:	Trenkwalder, Claudia, Kies, Bryan, Rudzinska, Monika, Fine, Jennifer, Nikl, Janos, Honczarenko, Krystyna, Dioszeghy, Peter, Hill, Dennis, Anderson, Tim, Myllyla, Vilho, Kassubek, Jan, Steiger, Malcolm, Zucconi, Marco, Tolosa, Eduardo, Poewe, Werner, Surmann, Erwin, Whitesides, John, Boroojerdi, Babak, Chaudhuri, Kallol Ray
Formato:	Texto
Lenguaje:	English
Publicado:	Wiley Subscription Services, Inc., A Wiley Company 2011
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3072524/ https://www.ncbi.nlm.nih.gov/pubmed/21322021 http://dx.doi.org/10.1002/mds.23441

Ejemplares similares

Rotigotine transdermal system and evaluation of pain in patients with Parkinson’s disease: a post hoc analysis of the RECOVER study
por: Kassubek, Jan, et al.
Publicado: (2014)

Rotigotine transdermal system for long-term treatment of patients with advanced Parkinson’s disease: results of two open-label extension studies, CLEOPATRA-PD and PREFER
por: LeWitt, Peter A., et al.
Publicado: (2012)

Transdermal rotigotine for the perioperative management of Parkinson’s disease
por: Wüllner, Ullrich, et al.
Publicado: (2010)

The Efficacy Profile of Rotigotine During the Waking Hours in Patients With Advanced Parkinson's Disease: A Post Hoc Analysis
por: LeWitt, Peter A., et al.
Publicado: (2016)

Overnight switch from ropinirole to transdermal rotigotine patch in patients with Parkinson disease
por: Kim, Han-Joon, et al.
Publicado: (2011)

Impulse control disorder related behaviours during long‐term rotigotine treatment: a post hoc analysis
por: Antonini, A., et al.
Publicado: (2016)

Treatment of moderate to severe restless legs syndrome: 2-year safety and efficacy of rotigotine transdermal patch
por: Högl, Birgit, et al.
Publicado: (2010)

Rotigotine's effect on PLM-associated blood pressure elevations in restless legs syndrome: An RCT
por: Bauer, Axel, et al.
Publicado: (2016)

Rotigotine in Combination with the MAO-B Inhibitor Selegiline in Early Parkinson’s Disease: A Post Hoc Analysis
por: Giladi, Nir, et al.
Publicado: (2016)

Rotigotine Transdermal Patch for Motor and Non-motor Parkinson’s Disease: A Review of 12 Years’ Clinical Experience
por: Raeder, Vanessa, et al.
Publicado: (2021)

Evaluation of rotigotine transdermal patch for the treatment of apathy and motor symptoms in Parkinson’s disease
por: Hauser, Robert A, et al.
Publicado: (2016)

Rotigotine transdermal patch and sleep in Parkinson’s disease: where are we now?
por: Rosa-Grilo, Miguel, et al.
Publicado: (2017)

Rotigotine transdermal system: a short review
por: Bunten, Sabine, et al.
Publicado: (2006)

Levodopa/rotigotine: Lack of efficacy: case report
Publicado: (2022)

Delirious episode secondary to rotigotine: the psychotic patch
por: Andreo Vidal, M. A., et al.
Publicado: (2023)

Evaluation of Heart Rate Variation Analysis during Rest and Tilting in Patients with Temporal Lobe Epilepsy
por: Ansakorpi, Hanna, et al.
Publicado: (2011)

Efficacy of Rotigotine at Different Stages of Parkinson’s Disease Symptom Severity and Disability: A Post Hoc Analysis According to Baseline Hoehn and Yahr Stage
por: Giladi, Nir, et al.
Publicado: (2016)

Restless legs syndrome: differential diagnosis and management with rotigotine
por: Merlino, Giovanni, et al.
Publicado: (2009)

Transdermal rotigotine for the perioperative management of restless legs syndrome
por: Högl, Birgit, et al.
Publicado: (2012)

EHMTI-0081. Use of rotigotine in chronic cluster headache
por: Savi, L, et al.
Publicado: (2014)

Behavioral and Neurophysiological Effects of Transdermal Rotigotine in Atypical Parkinsonism
por: Moretti, Davide Vito, et al.
Publicado: (2014)

The effects of the dopamine agonist rotigotine on hemispatial neglect following stroke
por: Gorgoraptis, Nikos, et al.
Publicado: (2012)

A Study for Expanding Application Sites for Rotigotine Transdermal Patch
por: Kujirai, Hitoshi, et al.
Publicado: (2020)

Leukoderma Induced by Rotigotine Patch, a Transdermal Dopamine Agonist
por: Talty, Ronan, et al.
Publicado: (2022)

Effects of Night-Time Use of Rotigotine on Nocturnal Symptoms in Parkinson's Disease
por: Vallderiola, Francesc, et al.
Publicado: (2015)

Transdermal rotigotine patch in Parkinson’s disease with a history of intestinal operation
por: Ogawa, Takashi, et al.
Publicado: (2018)

Rotigotine effect in prolonged disturbance of consciousness. Brief report of two cases
por: Corsi, Fabio Massimo, et al.
Publicado: (2020)

The Effect of Rotigotine Extended-Release Microspheres Alone or With Celecoxib on the Inflammatory Pain
por: Li, Keke, et al.
Publicado: (2020)

Effectiveness of Rotigotine plus intensive and goal-based rehabilitation versus Rotigotine alone in “de-novo” Parkinsonian subjects: a randomized controlled trial with 18-month follow-up
por: Ferrazzoli, D., et al.
Publicado: (2018)

Rotigotine Transdermal Patch in Parkinson’s Disease: A Systematic Review and Meta-Analysis
por: Zhou, Chang-Qing, et al.
Publicado: (2013)

Pharmacokinetics, Safety and Tolerability of Rotigotine Transdermal Patch in Healthy Japanese and Caucasian Subjects
por: Cawello, Willi, et al.
Publicado: (2013)

Fabrication, Optimization, and Evaluation of Rotigotine-Loaded Chitosan Nanoparticles for Nose-To-Brain Delivery
por: Tzeyung, Angeline Shak., et al.
Publicado: (2019)

A Systematic Review of the Usage of Rotigotine During Early and Advanced Stage Parkinson's
por: Rajendran, Avanthika, et al.
Publicado: (2023)

Cardiac surgery in the morning or not in the morning:“When?” is the question
por: Young, Martin E.
Publicado: (2021)

Tolerability of overnight rotigotine transdermal patch combined with intrajejunal levodopa infusion at 1 year: a 24-h treatment option in Parkinson’s disease
por: Lau, Yue Hui, et al.
Publicado: (2022)

Rotigotine in the Long-Term Treatment of Severe RLS with Augmentation: A Series of 28 Cases
por: Godau, Jana, et al.
Publicado: (2011)

Rotigotine is safe and efficacious in Atypical Parkinsonism Syndromes induced by both α-synucleinopathy and tauopathy
por: Moretti, Davide Vito, et al.
Publicado: (2014)

O060. Rotigotine improves drug-resistant cluster headache: a case series
por: Di Lorenzo, Cherubino, et al.
Publicado: (2015)

Lower irritation microemulsion-based rotigotine gel: formulation optimization and in vitro and in vivo studies
por: Wang, Zheng, et al.
Publicado: (2015)

Preparation and evaluation of rotigotine-loaded implant for the treatment of Parkinson’s disease and its evolution study
por: Wang, Aiping, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_5rd4hrnbhf19c03i3fuinjjl7m